Telix Pharmaceuticals Limited (ASX: TLX) announced the acquisition of RLS (USA) Inc. from RLS Group Ltd. This move expands Telix’s North American manufacturing and distribution capabilities, leveraging RLS’ 31 radiopharmacies and 100,000 sq ft of expansion space. The acquisition supports Telix’s strategy for a vertically integrated supply chain and enhances its radiometal production network, improving supply chain resilience and patient access across the U.S.

LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer.“To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S

LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer.“To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S